Patients’ frailty is a key factor negatively influencing survival, alongside with older age, less extensive tumor resection, corticosteroid treatment at baseline and the absence of promotor methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene [2]. Here, MGMT is linked to neoplasm.